Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Jazz Pharmaceuticals
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
China Medical University, China
IRCCS San Raffaele
Fox Chase Cancer Center
University of Iowa
Gruppo Oncologico Italiano di Ricerca Clinica
University Hospitals Bristol and Weston NHS Foundation Trust
M.D. Anderson Cancer Center
Emory University
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Daiichi Sankyo
University of Oklahoma
EMD Serono
Massachusetts General Hospital
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Seagen Inc.
Henan Cancer Hospital
Mabwell (Shanghai) Bioscience Co., Ltd.
Mayo Clinic
Spanish Oncology Genito-Urinary Group
Sun Yat-sen University
M.D. Anderson Cancer Center
Mayo Clinic
TheralaseĀ® Technologies Inc.
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sichuan Baili Pharmaceutical Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University
Centre Francois Baclesse
University of Florida
G1 Therapeutics, Inc.
Fudan University
National Cancer Institute (NCI)
Incyte Corporation
Nagoya University